Companies › Terran Biosciences Australia
1 active drug program in 4 registered trials: 4 Phase 1; Other; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate) Alpha-2A adrenergic receptor antagonist | ADRA2A | Phase 1 | Healthy | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05727189 | TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate) | Phase 1 | Healthy | Other | Dec 2027 |
| NCT05727189 | TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate) | Phase 1 | Healthy | Other | Dec 2027 |
| NCT05727189 | TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate) | Phase 1 | Healthy | Other | Dec 2027 |
| NCT05727189 | TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate) | Phase 1 | Healthy | Other | Dec 2027 |
Guangzhou Novaken Pharm Santen SAS Pharmazz ARS Pharmaceuticals BioXcel Therapeutics Teikoku Pharma USA Tecnoquimicas Tarian Pharma Alcon Research Acer Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.